MX2010007406A - Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). - Google Patents
Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).Info
- Publication number
- MX2010007406A MX2010007406A MX2010007406A MX2010007406A MX2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A MX 2010007406 A MX2010007406 A MX 2010007406A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- mif
- relates
- antigen
- present application
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101000950847 Homo sapiens Macrophage migration inhibitory factor Proteins 0.000 abstract 1
- 101001011645 Homo sapiens Muellerian-inhibiting factor Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 abstract 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 102000057097 human MIF Human genes 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a anticuerpos monoclonales y porciones de unión a antígeno de los mismos que específicamente se unen a la C-terminal o la región central del factor inhibidor de migración de macrófago (MIF). Estos anticuerpos anti-MIF y porciones de unión a antígeno de los mismos además inhiben la función biológica de MIF. La solicitud también se refiere a inmunoglobulinas de cadena pesada y ligera aisladas derivadas de los anticuerpos anti-MIF y moléculas de ácido nucleico que codifican dichas inmunoglobulinas. La presente solicitud también se refiere a un método para identificar anticuerpos anti-MIF, composiciones farmacéuticas que comprenden estos anticuerpos y un método para utilizar estos anticuerpos y composiciones para el tratamiento de condiciones relacionadas con el MIF.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1898808P | 2008-01-04 | 2008-01-04 | |
| US9468508P | 2008-09-05 | 2008-09-05 | |
| PCT/EP2008/011146 WO2009086920A1 (en) | 2008-01-04 | 2008-12-30 | Anti mif antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010007406A true MX2010007406A (es) | 2010-10-05 |
Family
ID=40535633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010007406A MX2010007406A (es) | 2008-01-04 | 2008-12-30 | Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20090220521A1 (es) |
| EP (4) | EP2548890A1 (es) |
| JP (1) | JP5502752B2 (es) |
| KR (2) | KR20160105943A (es) |
| CN (2) | CN103724430B (es) |
| AU (1) | AU2008346517B2 (es) |
| BR (1) | BRPI0821682A2 (es) |
| CA (1) | CA2711029A1 (es) |
| CY (1) | CY1117302T1 (es) |
| DK (1) | DK2231707T3 (es) |
| ES (3) | ES2791333T3 (es) |
| HR (1) | HRP20150224T1 (es) |
| IL (1) | IL206715A (es) |
| MX (1) | MX2010007406A (es) |
| NZ (3) | NZ586600A (es) |
| PL (2) | PL3118223T3 (es) |
| PT (1) | PT2231707E (es) |
| RS (1) | RS53906B1 (es) |
| RU (2) | RU2509777C2 (es) |
| SI (1) | SI2231707T1 (es) |
| WO (1) | WO2009086920A1 (es) |
| ZA (1) | ZA201004973B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821682A2 (pt) * | 2008-01-04 | 2015-06-16 | Baxter Int | Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. |
| WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| US9958456B2 (en) | 2011-10-07 | 2018-05-01 | Baxalta Incorporated | OxMIF as a diagnostic marker |
| JP2014530361A (ja) * | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ | Ｃｈｏ−ｍｉｆ遺伝子およびタンパク質の特性評価およびその使用 |
| AU2013203957B9 (en) * | 2012-04-16 | 2015-10-15 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Glucocorticoids |
| AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
| CA2878494A1 (en) | 2012-07-10 | 2014-01-16 | Baxter Healthcare S.A. | Anti-mif immunohistochemistry |
| HK1216265A1 (zh) * | 2012-12-07 | 2016-10-28 | Baxalta GmbH | 抗-mif抗體的細胞遷移測定方法 |
| WO2015106973A2 (en) * | 2014-01-03 | 2015-07-23 | Baxter Healthcare S.A. | Anti-mif immunohistochemistry |
| WO2016026956A1 (en) | 2014-08-22 | 2016-02-25 | Baxalta GmbH | Detection of cho-mif contaminations |
| WO2016156489A1 (en) | 2015-03-31 | 2016-10-06 | Baxalta GmbH | Dosage regimen for anti-mif antibodies |
| WO2016184886A1 (en) | 2015-05-18 | 2016-11-24 | Baxalta GmbH | Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras |
| EP3512880A1 (en) * | 2016-09-15 | 2019-07-24 | Ablynx NV | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| CN109868311B (zh) * | 2017-12-01 | 2023-10-20 | 上海市精神卫生中心 | Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用 |
| CN112334482A (zh) * | 2018-06-07 | 2021-02-05 | 翁科奥内研发有限责任公司 | 用于癌症治疗的抗oxMIF/抗CD3抗体 |
| EP3757252B1 (en) | 2019-06-28 | 2022-03-30 | Walter Ag | A coated cutting tool |
| AU2020397229A1 (en) * | 2019-12-06 | 2022-06-30 | Oncoone Research & Development Gmbh | Anti-oxMIF/anti-CD3 bispecific antibody constructs |
| WO2022069712A1 (en) * | 2020-10-02 | 2022-04-07 | Oncoone Research & Development Gmbh | IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY |
| WO2022167474A1 (en) | 2021-02-03 | 2022-08-11 | Oncoone Research & Development Gmbh | ANTI-oxMIF RADIOIMMUNOCONJUGATE |
| IL310958A (en) * | 2021-09-03 | 2024-04-01 | Oncoone Res & Development Gmbh | IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY |
| JP2025502557A (ja) * | 2022-01-10 | 2025-01-24 | フェノミック エーアイ | 抗ｃｔｈｒｃ１融合タンパク質及びその使用方法 |
| CN114573693A (zh) * | 2022-04-25 | 2022-06-03 | 中国人民解放军陆军军医大学 | 一种听觉发育中免疫调节分子mif抗体制备方法 |
| CN115814069B (zh) * | 2022-10-31 | 2023-07-21 | 四川大学华西医院 | Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途 |
| EP4676599A1 (en) | 2023-03-03 | 2026-01-14 | OncoOne Research & Development GmbH | Improved bispecific anti-tumor antigen/anti-hsg antibodies for pre-targeting of hyperproliferative disorders |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025171411A1 (en) * | 2024-02-09 | 2025-08-14 | Herophilus, Inc. | Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| US6774227B1 (en) * | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| JPH0977799A (ja) * | 1995-09-13 | 1997-03-25 | Sapporo Immuno Diagnostic Lab:Kk | ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ |
| CA2360106C (en) * | 1999-02-12 | 2012-10-30 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| WO2001064749A2 (en) | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| BRPI0821682A2 (pt) * | 2008-01-04 | 2015-06-16 | Baxter Int | Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. |
-
2008
- 2008-12-30 BR BRPI0821682-7A patent/BRPI0821682A2/pt not_active IP Right Cessation
- 2008-12-30 PL PL16183733T patent/PL3118223T3/pl unknown
- 2008-12-30 SI SI200831400T patent/SI2231707T1/sl unknown
- 2008-12-30 CA CA2711029A patent/CA2711029A1/en not_active Abandoned
- 2008-12-30 EP EP20120189220 patent/EP2548890A1/en not_active Withdrawn
- 2008-12-30 ES ES16183733T patent/ES2791333T3/es active Active
- 2008-12-30 ES ES14163839.5T patent/ES2623653T3/es active Active
- 2008-12-30 KR KR1020167023984A patent/KR20160105943A/ko not_active Ceased
- 2008-12-30 CN CN201410037650.3A patent/CN103724430B/zh not_active Expired - Fee Related
- 2008-12-30 PT PT08869976T patent/PT2231707E/pt unknown
- 2008-12-30 CN CN200880127872.7A patent/CN101983207B/zh not_active Expired - Fee Related
- 2008-12-30 JP JP2010541032A patent/JP5502752B2/ja not_active Expired - Fee Related
- 2008-12-30 NZ NZ586600A patent/NZ586600A/en not_active IP Right Cessation
- 2008-12-30 RS RS20150197A patent/RS53906B1/sr unknown
- 2008-12-30 NZ NZ611117A patent/NZ611117A/en not_active IP Right Cessation
- 2008-12-30 KR KR1020107017306A patent/KR101654678B1/ko active Active
- 2008-12-30 WO PCT/EP2008/011146 patent/WO2009086920A1/en not_active Ceased
- 2008-12-30 US US12/346,309 patent/US20090220521A1/en not_active Abandoned
- 2008-12-30 HR HRP20150224TT patent/HRP20150224T1/hr unknown
- 2008-12-30 EP EP14163839.5A patent/EP2754671B1/en active Active
- 2008-12-30 EP EP16183733.1A patent/EP3118223B8/en active Active
- 2008-12-30 RU RU2010132647/10A patent/RU2509777C2/ru active
- 2008-12-30 MX MX2010007406A patent/MX2010007406A/es active IP Right Grant
- 2008-12-30 DK DK08869976.4T patent/DK2231707T3/en active
- 2008-12-30 ES ES08869976.4T patent/ES2531629T3/es active Active
- 2008-12-30 AU AU2008346517A patent/AU2008346517B2/en not_active Ceased
- 2008-12-30 NZ NZ596409A patent/NZ596409A/xx not_active IP Right Cessation
- 2008-12-30 EP EP08869976.4A patent/EP2231707B1/en active Active
- 2008-12-30 PL PL08869976T patent/PL2231707T3/pl unknown
-
2010
- 2010-04-26 US US12/767,635 patent/US8668909B2/en active Active
- 2010-06-30 IL IL206715A patent/IL206715A/en active IP Right Grant
- 2010-07-14 ZA ZA2010/04973A patent/ZA201004973B/en unknown
-
2013
- 2013-12-03 RU RU2013153592/10A patent/RU2013153592A/ru not_active Application Discontinuation
-
2014
- 2014-01-17 US US14/157,967 patent/US20150023978A1/en not_active Abandoned
-
2015
- 2015-03-13 CY CY20151100250T patent/CY1117302T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010007406A (es) | Anticuerpos anti-factor inhibidor de migracion de macrofago (mif). | |
| MX2009006891A (es) | Anticuerpos cd44. | |
| MY160892A (en) | Antibodies to ccr2 | |
| EP2511301A3 (en) | Human antibodies to ERBB2 | |
| PH12014501872A1 (en) | P-cadherin antibodies | |
| TNSN07394A1 (en) | Antibodies to myostatin | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| WO2008060331A3 (en) | Antibodies to sars coronavirus | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| WO2008030611A3 (en) | Antibodies to bone morphogenic proteins and receptors therefor and methods for their use | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| TNSN06216A1 (en) | Antibodies to MAdCAM | |
| NO20092285L (no) | Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse | |
| EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора | |
| TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
| EA200602210A1 (ru) | Связывающие молекулы, способные нейтрализовать вирус бешенства, и их применение | |
| NO20090224L (no) | Anti-IL-6 monoklonale antistoffer og anvendelser derav | |
| NO20083697L (no) | Fremgangsmater for anvendelse av antistoffer mot human IL-22 | |
| MX2010001975A (es) | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso. | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| MX2014005570A (es) | El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios. | |
| UA112521C2 (uk) | Антитіло проти gdf8 людини | |
| TH148296A (th) | แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9) | |
| UA84539C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |